Form 4 for TXG 10x Genomics, Inc.
Accepted 2024-03-25 00:00:00 ET · period of report 2024-03-21 · accession 0001610717-24-000186 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-25 | 2024-03-21 | TXG | Saxonov Serge | CEO, Dir | A - Grant | $0.00 | +88.9K | 894.5K | +11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-03-21 | A | A | 88,854 | $0.00 | 894,518 | D | — | — | (F1) Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/16th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2024, subject to the Reporting Person continuing as a service provider through each such date. |